AstraZeneca PT receives Investment Bank Analyst Rating Update
- ByInvesting.com-
Symbol | Exchange | Currency | ||
|---|---|---|---|---|
| London | GBP | Real-time | ||
| London | GBP | Real-time | ||
| London | GBP | Real-time | ||
| BATS Europe | GBP | Delayed | ||
| BATS Europe | SEK | Delayed | ||
| NASDAQ | USD | Real-time | ||
| OTC Markets | USD | Delayed | ||
| Mexico | MXN | Delayed | ||
| Stockholm | SEK | Real-time | ||
| Frankfurt | EUR | Delayed | ||
| TradeGate | EUR | Delayed | ||
| Xetra | EUR | Delayed | ||
| Frankfurt | EUR | Delayed | ||
| Buenos Aires | ARS | Delayed |
Newark, New Castle, USA, March 13, 2023 (GLOBE NEWSWIRE) -- The global Influenza and COVID -19 vaccine market will be valued at 278.5 billion in 2030; the spike in cases of...
Keymed Bio and Lepu Biopharma out-licensed global rights for their antibody drug conjugate to AstraZeneca in a deal that includes $63 million upfront. Meanwhile, the $937 million...
Core earnings of $1.38 per share declined 17% year over year on a reported basis and 5% at constant exchange rates (CER).
EU attempting to revive Iran nuclear deal with market staying pessimistic Crude prices could rebound from oversold conditions but stay off 2022 highs Both Iran, US likely looking...
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company’s marketed products include Calquence, Enhertu, Faslodex, Imfinzi, Iressa, Koselugo, Lumoxiti, Lynparza, Orpathys, Tagrisso, and Zoladex for oncology; Andexxa/Ondexxya, Atacand, Atacand HCT, Atacand Plus, Brilinta/Brilique, Bydureon/Byetta, BCise, Byetta, Crestor, Evrenzo, Farxiga/Forxiga, Komboglyze/Kombiglyze XR, Lokelma, Onglyza, Qtern, Xigduo/Xigduo, and Zestril XR for cardiovascular, renal, and metabolism diseases; Accolate, Accoleit, Vanticon, Bevespi Aerosphere, Breztri Aerosphere, Bricanyl Respules and Turbuhaler, Daliresp/Daxas, Duaklir Genuair, Fasenra, Pulmicort, Rhinocort, Saphnelo, Symbicort, and Tezspire for respiratory and immunology; and Kanuma, Soliris, Strensiq, and Ultomiris for rare diseases. Its marketed products also comprise Synagis for respiratory syncytial virus; Fluenz Tetra/FluMist Quadrivalent for Influenza; and Vaxzevria and Evusheld for covid-19. The company serves primary care and specialty care physicians through distributors and local representative offices in the United Kingdom, rest of Europe, the Americas, Asia, Africa, and Australasia. It has a collaboration agreement with Neurimmune AG to develop and commercialize NI006; and Personalis, Inc. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.
Type | 5 Min | 15 Min | Hourly | Daily | Monthly |
|---|---|---|---|---|---|
| Moving Averages | Sell | Sell | Sell | Neutral | Buy |
| Technical Indicators | Strong Buy | Strong Buy | Strong Buy | Strong Buy | Strong Buy |
| Summary | Neutral | Neutral | Neutral | Buy | Strong Buy |
Name | Last | High | Low | Chg. | Chg. % | Vol. | Time | ||
|---|---|---|---|---|---|---|---|---|---|
| 18.14 | 18.21 | 17.63 | -0.13 | -0.71% | 2.91M | Toronto | |||
| 28.41 | 28.50 | 27.98 | -0.15 | -0.53% | 600.91K | Toronto | |||
| 0.165 | 0.17 | 0.165 | 0.00 | 0.00% | 74.38K | TSXV | |||
| 2.07 | 2.11 | 1.97 | -0.0200 | -0.96% | 31.50K | TSXV | |||
| 0.99 | 1.04 | 0.98 | -0.05 | -4.81% | 7.60K | Toronto | |||
| 0.81 | 0.81 | 0.78 | +0.0200 | +2.53% | 235.48K | TSXV | |||
| 0.22 | 0.245 | 0.215 | -0.0250 | -10.20% | 138.36K | TSXV | |||
| 1.57 | 1.58 | 1.52 | -0.01 | -0.63% | 116.41K | TSXV | |||
| 71.48 | 71.48 | 70.90 | 0.00 | 0.00% | 0.00 | Toronto | |||
| 0.03 | 0.03 | 0.03 | 0.00 | 0.00% | 0.00 | TSXV | |||
| 24.13 | 24.17 | 23.63 | +0.13 | +0.54% | 639.05K | Toronto | |||
| 64.81 | 65.59 | 62.50 | +1.250 | +1.97% | 614.03K | Toronto | |||
| 24.98 | 24.98 | 24.98 | 0.00 | 0.00% | 0.00 | Toronto | |||
| 11.00 | 11.00 | 10.61 | +0.37 | +3.48% | 3.32M | Toronto | |||
| 19.55 | 19.79 | 19.13 | -0.21 | -1.06% | 3.40M | Toronto |